Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
2.
J Allergy Clin Immunol Pract ; 7(5): 1497-1506, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30641146

RESUMEN

BACKGROUND: An Asthma Adherence Pathway (AAP) application, which is an Internet application that combines patient and clinician education strategies to promote adherence to asthma therapy, has been developed. OBJECTIVE: The primary objective of this pilot study was to evaluate the effectiveness of the AAP application with electronic adherence monitors on asthma control. Secondary objectives evaluated the effect of AAP and monitors on medication adherence, asthma symptoms, quality of life, psychosocial factors, and barriers to treatment. METHODS: Adult patients with asthma were randomly assigned either to intervention (n = 19) or control (n = 20) groups in this 3-month prospective study, and they completed the Asthma Control Questionnaire (ACQ). Intervention patients completed the AAP software and were given barrier-specific motivational interviewing adherence strategies and a SmartTrack device to monitor mometasone furoate/formoterol (MF/F) use. Clinicians in the interventional group received adherence management training. Interventional patients were given feedback regarding adherence findings at each visit. Treatment adherence was determined by the mean of 4 measures of doses taken over 3 months. Control patients were not monitored for MF/F adherence. RESULTS: The mean MF/F adherence in the intervention group was 81%. The intervention and control groups did not differ on the mean baseline ACQ. Thirteen intervention patients achieved the minimal important difference (defined as an improvement ≥0.5 units on the ACQ) compared with 6 control patients (P = .016). The intervention group showed greater improvement in the ACQ (0.75) than the control group (0.19) representing a moderate-to-large effect size of d = 0.638. CONCLUSIONS: The AAP was effective in promoting adherence and helped to improve asthma control. These findings provide preliminary validation of the AAP model.


Asunto(s)
Albuterol/uso terapéutico , Asma/tratamiento farmacológico , Broncodilatadores/uso terapéutico , Intervención basada en la Internet , Cumplimiento de la Medicación , Combinación Furoato de Mometasona y Fumarato de Formoterol/uso terapéutico , Entrevista Motivacional/métodos , Educación del Paciente como Asunto/métodos , Adulto , Anciano , Alergólogos/educación , Asma/fisiopatología , Educación a Distancia , Equipos y Suministros , Femenino , Humanos , Masculino , Persona de Mediana Edad , Proyectos Piloto , Neumólogos/educación , Adulto Joven
3.
Ann Allergy Asthma Immunol ; 122(5): 463-470, 2019 05.
Artículo en Inglés | MEDLINE | ID: mdl-30201469

RESUMEN

OBJECTIVE: Shared decision making (SDM) is becoming more commonly appreciated and used in medical practice as a way to empower patients who are facing treatment preference-sensitive conditions, such as allergic rhinitis, atopic dermatitis, food allergy, and persistent asthma. The purpose of this review is to educate the allergy health care provider about how SDM works and provide practical advice and allergist-specific SDM resources. DATA SOURCES: PubMed and online patient decision aid resources. STUDY SELECTIONS: Studies and reviews relevant to SDM and patient decision aids relevant to the allergy health care provider were selected for discussion. RESULTS: There are ethical, practical, economic, and psychological imperatives for the implementation of quality SDM, particularly for chronic diseases. Many benefits and barriers of SDM have been identified and models have been developed to encourage implementation of quality SDM. For the allergy health care provider, SDM for asthma has been shown to improve adherence, outcomes, and patient satisfaction with care. Patient decision aids are useful tools for SDM and have recently been developed for allergen immunotherapy, severe asthma, and atopic dermatitis. CONCLUSION: Effective SDM has been shown to improve adherence and lead to better outcomes. SDM should be universally implemented as a key component of patient-centered health care. Allergy health care providers should work with their patients to reach treatment decisions that align with their values and preferences.


Asunto(s)
Alergólogos/educación , Asma/terapia , Toma de Decisiones Clínicas/métodos , Toma de Decisiones Conjunta , Dermatitis Atópica/terapia , Participación del Paciente/métodos , Asma/inmunología , Asma/fisiopatología , Actitud del Personal de Salud , Enfermedad Crónica , Dermatitis Atópica/inmunología , Dermatitis Atópica/fisiopatología , Desensibilización Inmunológica/métodos , Humanos , Cooperación del Paciente/estadística & datos numéricos , Satisfacción del Paciente/estadística & datos numéricos , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA